Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multi-continent clinical trial

Acyclovir suppressive therapy (400 mg twice daily) reduces herpes simplex virus type 2 (HSV-2) associated genital ulcer disease (GUD) and lesional HSV shedding. In an international trial of acyclovir for HSV-2 suppression to prevent HIV acquisition (HPTN 039), acyclovir had a smaller effect on the f...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Fuchs, Jonathan, Celum, Connie, Wang, Jing, Hughes, James, Sanchez, Jorge, Cowan, Frances, Reid, Stewart, Delany-Moretlwe, Sinead, Corey, Lawrence, Wald, Anna
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2856478/
https://ncbi.nlm.nih.gov/pubmed/20214474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/651381
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak